Browse Title Index


 
Issue Title
 
Vol 25, No 1 (2024) Cost-Effectiveness of Dimethyl Fumarate Compared to Teriflunomide for Relapsing Remitting Multiple Sclerosis Patients in Italy: Results of an Updated Analysis Details   HTML   PDF
Lorenzo Mantovani, Paolo Angelo Cortesi, Michele Molina, Laura Santoni, Luca Prosperini
 
Vol 23, No 1 (2022) Cost-effectiveness of Empagliflozin, in Addition to Metformin, in Patients with Type 2 Diabetes in Italy Abstract   HTML   PDF
Edoardo Mannucci, Gianni Ghetti
 
Vol 15, No 4 (2014) Cost-effectiveness of intravitreal therapy in Age-Related Macular Degeneration Abstract   HTML   PDF
Piergiorgio Neri, Ilir Arapi, Chiara Maria Eandi, Vittorio Pirani, Cesare Mariotti, Alfonso Giovannini
 
Vol 15, No 1 (2014) Cost-effectiveness of tenofovir in the treatment of patients with chronic hepatitis B: data from literature Abstract   HTML   PDF
Massimo Fasano, Giorgio L. Colombo, Sergio Di Matteo, Claudia Randazzo, Gioacchino Angarano, Teresa Antonia Santantonio
 
Vol 17, No 3 (2016) Cost-effectiveness profile, organizational implications and patient preferences on the use of exogenous TSH therapy (Thyrogen®) vs. THW in thyroid residue ablation in Italy Abstract   HTML   PDF
Gianluca De Danieli, Fabio Monari, Renzo Lazzarini, Filippo Cipriani
 
Vol 9, No 3 (2008) Cost-efficacy analysis of hormonal treatments for advanced prostate cancer Abstract   PDF
Sergio Iannazzo, Lorenzo Pradelli
 
Vol 3, No 2 (2002) Costi del trattamento con oloprazina nelle fasi iniziali della schizofrenia Abstract   PDF
Domenico Berardi, Maddalena Dell’Atti, Francesca Russo, Virginia Vagnini, Luca Guidi, Eric T. Edgell
 
Vol 6, No 2 (2005) Costi e bisogni sanitari degli anziani non autosufficienti presso le strutture residenziali: strategie e interventi per una popolazione che invecchia Abstract   PDF
Marta Moro, Chiara Salvato, Gianni Terrazzani, Donatella Serraglia, Cristina Saramin, Pietro Giusti, Alessandro Chinellato
 
Vol 5, No 1 (2004) Costi ed effetti di Risperidone Long Acting (RLA) rispetto ad antipsicotici atipici nel trattamento dei soggetti schizofrenici in Italia Abstract   PDF
Lorenzo G. Mantovani, Patrizia Berto, Anna D. Ausilio, Bart Heeg
 
Vol 4, No 1 (2003) Costi sanitari di un programma vaccinale: analisi di minimizzazione dei costi Abstract   PDF
G. L. Colombo, A. Muzio, R. Giordani
 
Vol 6, No 3 (2005) Costo/efficacia della prevenzione di infezioni alle prime vie aeree mediante un estratto batterico immunostimolante aspecifico (OM-85) Abstract   PDF
Orietta Zaniolo, Lorenzo Pradelli, Mario Eandi
 
Vol 5, No 1 (2004) Costo-efficacia dell’amfotericina B liposomiale nella terapia dell’aspergillosi invasiva Abstract   PDF
Mario Eandi
 
Vol 2, No 1 (2001) Costruzione di un modello decisionale per valutare la costo/efficacia delle strategie alternative nella terapia della polmonite acquisita in comunità Abstract   PDF
Mario Eandi
 
Vol 8, No 2 (2007) Costs and efficacy ofolanzapine and risperidone in schizophrenia Abstract   PDF
Vittorio Mapelli
 
Vol 10, No 2 (2009) Costs of diabetes in Italy Abstract   PDF
Orietta Zaniolo
 
Vol 14, No 2 (2013) Costs of treatment of haemophilia A in Italy: comparison of the use of plasma-derived and recombinant FVIII using a discrete event simulation (DES) model Abstract   HTML   PDF
Mario Eandi, Lorenzo Pradelli, Massimiliano Povero
 
Vol 9, No 1 (2008) Cost-utility analysis of abatacept in rheumatoid arthritis in Italy Abstract   PDF
Simona de Portu, Lorenzo Giovanni Mantovani, Ignazio Olivieri
 
Vol 15, No 4 (2014) Cost‑effectiveness analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients Abstract   HTML   PDF
Lorenzo Pradelli, Mario Calandriello, Roberto Di Virgilio, Marco Bellone, Marco Tubaro
 
Vol 15, No 3 (2014) Cost‑effectiveness analysis of hexaminolevulinate (Hexvix®) guided cystoscopy in Non‑Muscle Invasive Bladder Cancer patients (NMIBC) in Italy Abstract   HTML   PDF
Craig Bennison, Stephanie Stephens, Giario Natale Conti
 
Vol 13, No 1 (2012) Could the choice of patient versus proxy ratings for assessing quality of life in dementia affect resource allocation in health care? Abstract   HTML   PDF
Jenny Alwin, Thor-Henrik Brodtkorb
 
Vol 1, No 1 (2000) Creare Valore Sanitario: nuove prospettive per il management delle aziende sanitarie Abstract   PDF
Giorgio Donna, Salvatore Nieddu
 
Vol 1, No 2 (2000) Creazione di valore sanitario e sistemi di finanziamento: il caso del dipartimento di salute mentale Abstract   PDF
Carmine Munizza, Salvatore Nieddu
 
Vol 21, No 1 (2020) Critical Review of the Pivotal Studies of Four rFVIII Products for the Treatment of Hemophilia A Patients: The Role of Octocog Alfa Abstract   HTML   PDF
Matteo Nicola Dario Di Minno, Lucia D'Angiolella, Paolo Angelo Cortesi, Angelo Claudio Molinari, Lorenzo Giovanni Mantovani
 
Vol 10, No 3 (2009) Dabigatran in the prevention of venous thromboembolism after major orthopedic surgery Abstract   PDF
Orietta Zaniolo
 
Vol 9, No 3 (2008) Daptomycin (Cubicin) in patients with complicated skin or soft-tissue infections Abstract   PDF
Viola Sacchi
 
Vol 25, No 1 (2024) Decatecholaminization of Septic Shock Patients in Intensive Care Unit: an Economic Assessment in the Italian Setting Abstract   HTML   PDF
Alfredo Del Gaudio, Assunta Caiazza, Luana Bortone, Sonia Tomasso, Ilaria Bozzari, Laura Vincenzi, Gianluca Furneri, Luigi Tritapepe
 
Vol 9, No 2 (2008) Decision analytic economic paliperidone ER in relapsing schizophrenic patients in Italy Abstract   PDF
Patrizia Berto, Cristina Negrini, Luigi Ferrannini
 
Vol 17, No 2 (2016) Demand for healthcare by the elderly in developing countries Details   HTML   PDF
Yinka Kehinde Binuomoyo, Abimbola Oluseyi Ogunsola
 
Vol 12, No 2S (2011) DENALI: il Data Warehouse di Sanità Pubblica della Regione Lombardia Details   PDF
Giancarlo Cesana, Carla Fornari, Virginio Chiodini, Fabiana Madotto, Luca Merlino, Lorenzo G. Mantovani
 
Vol 20, No 1 (2019) Developing a Model for the Establishment of Pre-Hospital Emergency Medicine Bases in the Northern Provinces of Iran Abstract   HTML   PDF
Azadeh Ahmadi Dashtiyan, Iravan Masoudi Asl, Leila Riahi, Mahmood Mahmoodi
 
Vol 14, No 4 (2013) Direct medical costs of COPD diagnosis and treatment, Eastern vs Western European country – examples of Serbia and Belgium Abstract   HTML   PDF
Mihajlo B Jakovljevic, Zorica Lazic, Nick Verhaeghe, Slobodan Jankovic, Olgica Gajovic, Lieven Annemans
 
Vol 4, No 2 (2003) Durata e costo delle visite in medicina generale: il progetto DYSCO Abstract   PDF
Livio Garattini, Emanuela Castelnuovo, Davide Lanzeni, Cecilia Viscarra, DYSCO VISITE Gruppo di studio DYSCO VISITE
 
Vol 1, No 2 (2000) È possibile coniugare risparmio e miglioramento nelle aziende USL? Abstract   PDF
Sergio Sabbatani
 
Vol 7, No 4 (2006) Economic and clinical value of levofloxacin Abstract   PDF
Mario Eandi, Orietta Zaniolo
 
Vol 15, No 3 (2014) Economic burden of Communicable and Non-communicable Diseases in Jamaica: Is our research focus where it should be? Details   HTML   PDF
Christine Fray-Aiken
 
Vol 23, No 1 (2022) Economic Consequences of Administering Obinutuzumab as a Short Duration Infusion in Italian Patients with Advanced Follicular Lymphoma: A Cost Analysis Abstract   HTML   PDF
Marco Bellone, Lorenzo Pradelli, Rita Tavarozzi, Marco Ladetto, Giuliana Nepoti, Emanuele Guardalben, Daniela Ghislieri
 
Vol 10, No 3 (2009) Economic crisis and consumption of medical resources in Italy Details   PDF
Mario Eandi
 
Vol 20, No 1 (2019) Economic Evaluation of Different Organizational Models for the Management of Patients with Hepatitis C Abstract   HTML   PDF
Stefano Fagiuoli, Luisa Pasulo, Franco Maggiolo, Rosaria Spinella, Paolo Del Poggio, Roberto Boldizzoni, Mariella Di Marco, Alessandro Aronica, Chiara Benedetti, Paolo Correale, Chiara Garavaglia, Carlo Nicora
 
Vol 10, No 2 (2009) Economic evaluation of temsirolimus on the basis of the results of the ARCC (Advanced Renal-Cell Carcinoma) study Abstract   PDF
Simona de Portu, Giacomo Carteni, Andrea Belisari
 
Vol 7, No 3 (2006) Economic evaluation of the CARDS study Abstract   PDF
Simona de Portu, Enrica Menditto, Lorenzo G. Mantovani
 
Vol 14, No 3 (2013) Economic evaluation of the chronic hepatitis B treatment strategies in Italy Abstract   HTML   PDF
Sergio Iannazzo, Barbara Coco, Maurizia Brunetto, Francesca Rossetti, Antonietta Caputo, Maria De Francesco, Ferruccio Bonino
 
Vol 11, No 2 (2010) Economic evaluation of the use of saxagliptin in the treatment of type 2 diabetes in Italy Abstract   PDF
Marco Cristiani, Anna Citarella, Andrea Belisari, Guido Didoni, Lorenzo Giovanni Mantovani, Sabato Montella
 
Vol 15, No 4 (2014) Economic impact of the use of Hyalubrix® in the treatment of hip osteoarthritis in Italy Abstract   HTML   PDF
Alberto Migliore, Andrea Belisari, Lucia S. D'Angiolella, Emanuele Bizzi, Umberto Massafra, Prisco Piscitelli, Lorenzo Giovanni Mantovani
 
Vol 18, No 1 (2017) Economic implications in inflammatory bowel disease: results from a retrospective analysis in an Italian Centre Abstract   HTML   PDF
Angela Variola, Arianna Massella, Andrea Geccherle, Paolo Bocus, Roberto Tessari, Teresa Zuppini, Roberto Ravasio
 
Vol 19, No 1 (2018) Editorial Staff Disclosure (2018) Details   HTML   PDF
Ombretta Bandi
 
Vol 10, No 4 (2009) Effectiveness and cost of treatment with maraviroc in HIV infection Abstract   PDF
Viola Sacchi, Lorenzo Pradelli
 
Vol 20, No 1 (2019) Effectiveness of Long-Acting Injectable Antipsychotics in Schizophrenia: A Literature Review and Bayesian Meta-Analysis Informing Economic Considerations Abstract   HTML   PDF
Orietta Zaniolo, Gianni Ghetti, Massimiliano Povero, Lorenzo Pradelli
 
Vol 3, No 1 (2002) Efficienza tecnologica e produttiva delle strutture trasfusionali in Italia Abstract   PDF
Dante Cornago, Livio Garattini
 
Vol 13, No 2S (2012) Emilia Romagna Abstract   HTML   PDF
Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni
 
Vol 9, No 1S (2008) Emilia Romagna Abstract   PDF
Maria Caterina Cavallo, Filippo Cipriani, Simone Gerzeli, Nadia Demarteau, Alessia Marocco, Francesco Bamfi
 
Vol 9, No 3 (2008) Entecavir (Baraclude) in patients with chronic hepatitis B virus (HPV) infection Abstract   PDF
Viola Sacchi
 
Vol 12, No 2S (2011) Epidemiologia, prevenzione e trattamento delle malattie cardiovascolari: evidenze dal database della medicina generale Details   PDF
Giampiero Mazzaglia, Alessandro Filippi, Lorenzo G. Mantovani, Gianluca Furneri, Carlo Niccolai, Jacopo Cricelli, Achille P. Caputi, Ovidio Brignoli, Claudio Cricelli
 
Vol 9, No 2 (2008) Epidemiological and economic aspects of diabetes in the Campania Region, Italy Abstract   PDF
Simona Cammarota, Andrea Morsanutto, Enrica Menditto, Anna Citarella, Simona de Portu
 
Vol 9, No 4 (2008) Epidemiology and costs of HPV infection: review of the evidence Abstract   PDF
Francesco Bamfi, Alessia Marocco, Stefano Capri, Mario Giovanni Sideri
 
Vol 18, No 1 (2017) Equilibrium between resources and expenditure of health sector of Social Security Fund: a case study of Iran Abstract   HTML   PDF
Azadeh Ahmadi Dashtian, Mohsen Mardali
 
Vol 11, No 2 (2010) Equity of access to innovative drugs and sustainability of pharmaceutical expenditure Details   PDF
Mario Eandi
 
Vol 7, No 1 (2006) Errata corrige: “Valutazione clinica e metabolica dell’impiego dell’insulina Lispro in pazienti con diabete mellito scompensato” Details   PDF
Antonio Uneddu, Tito Antonio Paolini
 
Vol 20, No 1 (2019) Erratum: Effectiveness of Long-Acting Injectable Antipsychotics in Schizophrenia: A Literature Review and Bayesian Meta-Analysis Informing Economic Considerations Abstract   HTML   PDF
[No authors listed]
 
Vol 13, No 3S (2012) Essential to increase the use of generics in Europe to maintain comprehensive health care? Abstract   HTML   PDF
Brian Godman, Marion Bennie, Christoph Baumgärtel, Ljiljana Sović-Brkičić, Thomas Burkhardt, Jurij Fürst, Kristina Garuoliene, Miguel Gomes, Vanda Markovic-Pekovic, Andrew Martin, Catherine Sermet, Peter Skiold, Menno van Woerkom, Luka Voncina, Lars L. Gustafsson
 
Vol 19, No 1 (2018) Estimating the cost-effectiveness of treatment for prevention of thromboembolic events in at-risk adults with non-valvular atrial fibrillation Abstract   HTML   PDF
Marco Bellone, Lorenzo Pradelli, Mario Bo
 
Vol 12, No 1 (2011) Estimation of economic consequences of GOLD guidelines adoption in the Italian clinical practice Abstract   PDF
Orietta Zaniolo, Germano Bettoncelli, Giancarlo Bosio, Lorenzo Mantovani, Riccardo Pistelli, Adriano Vaghi, Marco Villa, Sergio Iannazzo, Francesco Bamfi, Vincenzo Frizzo, Roberto Walter Dal Negro
 
Vol 14, No 2 (2013) European and Italian regulation on orphan medicinal products Abstract   HTML   PDF
Roberta Joppi
 
Vol 7, No 1 (2006) European health information system and cardiovascular diseases Details   PDF
Mario Eandi
 
Vol 9, No 1 (2008) Evaluation of antimicrobial consumption in Campania Region, Italy Abstract   PDF
Simona Cammarota, Anna Citarella, Enrica Menditto, Simona de Portu
 
Vol 9, No 1 (2008) Evaluation of health resources expenditure in two groups of psychotic patients treated with olanzapine and typical neuroleptics in a Italian Mental Health Department in Calabria Region Abstract   PDF
Anna Caputo, Luca Guidi, Giovanni Biricolti, Sergio Torchia
 
Vol 20, No 1 (2019) Evaluation of patients treated for diabetic retinopathy: an analysis of the administrative databases of the Lazio Region Abstract   HTML   PDF
Francesco Mennini, Lorella Lombardozzi, Alessandra Mecozzi, Paolo Sciattella
 
Vol 18, No 1 (2017) Evaluation of the cost saving potential of introducing Benepali® and Flixabi® on the European and Italian markets Abstract   HTML   PDF
Cristina Negrini, Emi Psachoulia
 
Vol 9, No 3 (2008) Evolution of global drug market and amrket access Details   PDF
Mario Eandi
 
Vol 6, No 4 (2005) Evoluzione del mercato farmaceutico nei primi nove mesi del 2005 Details   PDF
Mario Eandi
 
Vol 4, No 1S (2003) Evoluzione storica della farmacoutilizzazione degli anti-ipertensivi in Italia (1988-1998) Abstract   PDF
Enrico Bologna, Pierluigi Russo, Sabrina Licata, Liliana Civalleri, Luciano Caprino
 
Vol 15, No 2 (2014) Experiences of including costs of added life years in health economic evaluations in Sweden Abstract   HTML   PDF
Laura Pirhonen, Thomas Davidson
 
Vol 21, No 1 (2020) Extended Half-life rFVIII for the Treatment of Hemophilia A: Drugs Consumption and Patients’ Perspective Abstract   HTML   PDF
Daniela Paola Roggeri, Ezio Zanon, Chiara Biasoli, Alessandro Roggeri
 
Vol 4, No 4 (2003) Farmaci antipertensivi a confronto: costi e benefici per il paziente e la collettività Abstract   PDF
Francesco Vittorio Costa
 
Vol 2, No 4 (2001) Farmaci orfani e malattie rare: la situazione in Italia Abstract
S. Martina, C. Denti, E. Daina, L. Garattini
 
Vol 2, No 3 (2001) Farmaci orfani e malattie rare: un confronto internazionale delle normative di riferimento Abstract   PDF
S. Martina, C. Denti, L. Garattini
 
Vol 4, No 1S (2003) Farmacoeconomia dei COXIB nella patologia osteoarticolare: revisione della letteratura Abstract   PDF
Pierluigi Russo, Luca Degli Esposti, Alessandro Capone, Ezio Degli Esposti, Luciano Caprino
 
Vol 8, No 2S (2007) Farmacoeconomia e malattie cardiovascolari Details   PDF
Lorenzo G. Mantovani, Andrea Morsanutto, Simona De Portu
 
Vol 5, No 3 (2004) Farmacoeconomia e outcomes research Abstract   PDF
Ermanno Attanasio
 
Vol 5, No 4 (2004) Farmacoeconomia ed etica: cure sostenibili e rispetto della persona Abstract   PDF
Antonio G. Spagnolo, Roberta Minacori
 
Vol 4, No 1S (2003) Farmacoepidemiologia e farmacoeconomia della terapia anti-ipertensiva: uno studio osservazionale della popolazione della Asl di Ravenna Abstract   PDF
Luca Degli Esposti, Alessandro Capone, Mirko Di Martino, Stefania Saragoni, Samuele Berlini, Pierluigi Russo, Ezio Degli Esposti
 
Vol 7, No 3 (2006) First drug utilization data related to an anticholinergic agent recently marketed in Italy Abstract   PDF
Carlo Lucioni, S. Mazzi, C. Cerra, S. Lottaroli
 
Vol 14, No 2 (2013) First-line HIV treatment: evaluation of backbone choice and its budget impact Abstract   HTML   PDF
Orietta Zaniolo, Massimiliano Povero, Paolo Bonfanti, Marco Borderi, Massimo Medaglia
 
Vol 4, No 3 (2003) Fluoxetina: profilo terapeutico e farmacoeconomico di un prodotto generico Abstract   PDF
Carlo Della Pepa, Mario Eandi
 
Vol 2, No 3 (2001) Fluvoxamina: profilo farmacoeconomico Abstract   PDF
Mario Eandi
 
Vol 6, No 3 (2005) Forme galeniche e qualità di vita: il caso di tramadolo Abstract   PDF
Orietta Zaniolo
 
Vol 9, No 1S (2008) Friuli Venezia Giulia Abstract   PDF
Maria Caterina Cavallo, Filippo Cipriani, Simone Gerzeli, Nadia Demarteau, Alessia Marocco, Francesco Bamfi
 
Vol 13, No 2S (2012) Friuli-Venezia Giulia Abstract   HTML   PDF
Roberto Gasparini, Donatella Panatto, Bruna Dirodi, Rosa Prato, Gianni Amunni, Valter Turello, Luigi Sudano, Paolo Cristoforoni, Sara Boccalini, Paolo Bonanni
 
Vol 13, No 3S (2012) From generic to biosimilar drugs: why take an innovative pace? Abstract   HTML   PDF
Fereshteh Barei, Claude Le Pen, Steven Simoens
 
Vol 21, No 1 (2020) Funding Innovation Thanks to Anti-TNF-α Biosimilars Uptake: The Economic Impact in Italy Abstract   HTML   PDF
Massimiliano Povero, Lorenzo Pradelli
 
Vol 11, No 2 (2010) Fungal infections today: size of the problem and focus on the initial cost of therapy with echinocandin Abstract   PDF
Mario Venditti
 
Vol 12, No 2 (2011) Gefitinib: a pharmacoeconomic profile of its use in patients with Non Small Cell Lung Cancer EGFR+ Abstract   HTML   PDF
Viola Sacchi
 
Vol 13, No 3S (2012) Generic and biosimilar medicines: quid? Abstract   HTML   PDF
Steven Simoens
 
Vol 6, No 4 (2005) Gli antagonisti del recettore GPIIb/IIIa: farmacologia, clinica ed economia nelle sindromi coronariche acute NSTEMI e nelle rivascolarizzazioni per via percutanea Abstract   PDF
Lorenzo Pradelli
 
Vol 4, No 1 (2003) Gli inibitori della pompa protonica nelle patologie acido correlate: il ruolo di rabeprazolo in una strategia di cost-minimisation Abstract   PDF
Giorgio L. Colombo, Andrea Muzio
 
Vol 2, No 4 (2001) Gli studi di “cost of illness” in Italia: una review della letteratura Abstract
Andrea Bracco
 
Vol 15, No 1 (2014) GOLD guidelines adherence impact on the NHS budget Abstract   HTML   PDF
Alessandro Guasconi, Claudio Ripellino, Franca Heiman
 
Vol 9, No 4 (2008) Growing impact of pharmacogenomic on drug development and personalized medicine Details   PDF
Mario Eandi
 
Vol 12, No 2S (2011) Health Technology Assessment Details   PDF
Lorenzo G. Mantovani, Giuseppe La Torre, Giancarlo Cesana, Walter Ricciardi
 
Vol 22, No 1S (2021) Health Technology Assessment on the use of the Wearable Cardioverter Defibrillator in Patients with Myocardial Infarction and with ICD Explant Abstract   HTML   PDF
Paolo Angelo Cortesi, Giovanni Luca Botto, Lucia D'Angiolella, Luciana Scalone, Roberto De Ponti, Giuseppe Boriani, Lorenzo Giovanni Mantovani
 
Vol 19, No 1 (2018) Healthcare Resources Use in Patients with Human Immunodeficiency Virus (HIV). Real-World Evidence From Six Italian Local Health Units Abstract   HTML   PDF
Valentina Perrone, Diego Sangiorgi, Stefano Buda, Margherita Andretta, Silvio Borrè, Chiara Cattaruzzi, Gina Gasperini, Fabio Lena, Alessia Pisterna, Luca Degli Esposti
 
101 - 200 of 481 Items << < 1 2 3 4 5 > >>